JASO, HIL, PPHM - CRWESelect.com Stock News! JA Solar Holdings Co., Hill International, Peregrine Pharmaceuticals (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) December 29, 2011 -- To view video, and read the full article visit URL http://crweselect.com/27969/stock-alerts/jaso-hil-pphm-crweselectcom-stock-news-ja-solar-holdings-co-hill-international-peregrine-pharmaceuticals-video-included-inside/

JA Solar Holdings Co., Ltd. (NASDAQ:JASO)

JASO, announced today that it has entered into an agreement with Solarhybrid AG ("Solarhybrid"), a Germany-based project developer and general contractor for turn-key utility-scale solar power projects, to supply 19 MW of solar modules to Solarhybrid's Allstedt I solar power plant in Halle, Germany. JA Solar is the exclusive solar module supplier to the project.

JASO is a leading manufacturer of high-performance solar power products. The company sells its products to solar manufacturers worldwide, who assemble and integrate solar cells into modules and systems that convert sunlight into electricity for residential, commercial, and utility-scale power generation.

For more information about JASO please visit http://www.jasolar.com/

****

Hill International, Inc. (NYSE:HIL)

HIL, announced today that it has been awarded a contract by the Iraqi Ministry of Youth and Sports to provide project management services in connection with construction of the new Al Anbar Olympic Stadium in Al Anbar, Iraq. The two-year contract has an estimated value to Hill of approximately IQD 3.8 billion ($3.3 million).

HIL, with 3,100 employees in 100 offices worldwide, provides program management, project management, construction management and construction claims and consulting services. Engineering News-Record magazine recently ranked Hill as the 8th largest construction management firm in the United States.

For more information about HIL please visit http://www.hillintl.com/

****

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM)

PPHM provided today an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV). Patients were randomized in the three-arm study to receive one of two doses of bavituximab (0.3mg/kg or 3mg/kg) or pegylated interferon alpha-2a, in combination with ribavirin. The goals of the study were to determine if bavituximab plus ribavirin has a better safety profile as compared to interferon plus ribavirin, to confirm that the combination of bavituximab and ribavirin has antiviral activity defined as 12 week early virologic response (EVR)(1) and to compare antiviral activity of peg-interferon plus ribavirin versus bavituximab plus ribavirin.

PPHM is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers.

For more information about PPHM please visit http://www.peregrineinc.com/

To read the full article visit URL http://crweselect.com/27969/stock-alerts/jaso-hil-pphm-crweselectcom-stock-news-ja-solar-holdings-co-hill-international-peregrine-pharmaceuticals-video-included-inside/

***************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

JASOcrweselect1229
HILcrweselect1229
PPHMcrweselect1229

hil     Hill International     JA Solar Holdings Co.     JASO     Peregrine Pharmaceuticals     Phase II bavituximab study     PPHM     Solarhybrid AG